logo
Where's the Value in Health Care?
Substantial Returns to Health-Care Spending
The Return on Investment in Health Care
Economic Evaluation in Health Care
Bringing Health Economic Modeling to the 21st Century
The Future of Health Economic Modeling
What Decision-Makers Want and What They Have Been Getting
Health Resource Utilization and Medical Care Cost of Acute Care Elderly Unit Patients
Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden
Linguistic Validation of the US Spanish Work Productivity and Activity Impairment Questionnaire, General Health Version
USING TABLET PCS FOR SMOKING HAZARDS EDUCATION IN A METHADONE CLINIC
THE PREVALENCE OF SUBJECTIVELY EXPERIENCED ADVERSE DRUG REACTIONS. A NATIONWIDE SURVEY IN SWEDEN
DETERMINANTS OF NON-COMPLIANCE WITH BISPHOSPHONATE THERAPY IN WOMEN WITH POST-MENOPAUSAL OSTEOPOROSIS
OCCURRENCE OF THROMBOCYTOPENIA AFTER ORTHOPEDIC SURGERIES IN PATIENTS TREATED WITH FONDAPARINUX, DALTEPARIN, ENOXAPARIN OR UNFRACTIONATED HEPARIN
THE ECONOMIC AND HEALTH CONSEQUENCES IN SWEDEN OF MANAGING BRADYCARDIA WITH ADAPTA® COMPARED TO A STANDARD DUAL CHAMBER PACEMAKER
ECONOMIC BURDEN OF WORK LOSS AMONG SUFFERERS OF LYMPHATIC FILARIASIS
THE EFFECT OF ORGAN THREATENING AND MENTAL HEALTH CO-MORBIDITIES ON MEDICAL COSTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
FREQUENCY AND COST OF DISABILITY AMONG EMPLOYED INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
RECENT POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT HAVE REDUCED COST DRAMATICALLY
THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS IN AN EMPLOYED POPULATION
DETERMINANTS OF GENERIC ENTRY IN LAST DECADE
PRESCRIPTION DRUG INSURANCE AND ITS EFFECT ON UTILIZATION AND HEALTH OF THE ELDERLY
A BAYESIAN ESTIMATION OF AN AVERAGE SF-6D PREFERENCE BASED SCORE FROM COMMONLY REPORTED SF-12 STATISTICS
QUANTIFYING PATIENTS' RISK-BENEFIT TRADEOFF PREFERENCES
RACIAL DIFFERENCES IN PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE ASSESSMENT
CONVERTING THE SCORES OF A CLINICAL INSTRUMENT FOR MEASURING PAIN TO A PREFERENCE BASED ONE
TRENDS IN MEDICATION PRESCRIBING FOR CHILDREN WITH SLEEP DISORDERS IN US OUTPATIENT SETTINGS
COST-EFFECTIVENESS OF TELITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
LONG TERM SURVIVAL AS A FUNCTION OF AIRWAY OBSTRUCTION (FEV1) IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH CARE UTILIAZATION AND USE OF SALMETEROL AMONG SUBJECTS WITH ASTHMA
PHARMACOECONOMIC EVALUATION OF SINGLE DOSE AZITHROMYCIN EXTENDED RELEASE (AZ-ER) FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)
THE COST-EFFECTIVENESS OF ZEMPLAR IN THE NETHERLANDS
SHORT-TERM COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE
COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA
WITHDRAWN
SELF REPORTED PREDICTORS OF DEPRESSIVE SYMPTOMATOLOGY IN AN ELDERLY POPULATION WITH TYPE 2 DIABETES MELLITUS
QUALITY OF LIFE IN PEOPLE WITH AND AT RISK FOR TYPE 2 DIABETES
STRESS AND COPING STRATEGIES ASSOCIATED WITH PHYSICAL AND MENTAL HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
USE OF MEDICATION COVERAGE METHODOLOGY IN MEASUREMENT OF PATIENT COMPLIANCE WITH PHARMACOTHERAPY
COST-EFFECTIVENESS OF A GLAUCOMA-SCREENING PROGRAM
AN AUDIT OF 106 ECONOMIC ANALYSES CONTAINED IN AMCP DOSSIER SUBMISSIONS 2002-2005
NATIONAL ESTIMATES AND ASSOCIATED FACTORS OF ANTIPSYCHOTIC USE IN AMBULATORY CARE FROM 1996 TO 2003
VALIDATION OF THE HYPERPIGMENTATION TREATMENT SATISFACTION QUESTIONNAIRE (HPTSQ)
VALIDATION OF THE WORK PRODUCTIVITY QUESTIONNAIRE
RISK INDICATORS FOR SELF-REPORTED JOINT PAIN AND MOTION LIMITATION OUTCOMES IN HEMOPHILIA PATIENTS-THE HEMOPHILIA COST AND IMPACT OF DISEASE STUDY-PART V
THE IMPACT OF ABNORMAL UTERINE BLEEDING ON HEALTH-RELATED QUALITY OF LIFE
ECONOMIC EVALUATION OF A 90-DAY RETAIL PRESCRIPTION DRUG PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING
ESTIMATING OUT-OF-POCKET PHARMACEUTICAL EXPENDITURES UNDERTHE NEW MEDICARE DRUG LAW FOR PATIENTS WITH MENTAL DISORDERS-AN ANALYSIS OF CLAIMS DATA FROM RETIREE MEDICAL PLANS
DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES
RACIAL/ETHNIC DISPARITIES IN LENGTH OF STAY AND COST OF INPATIENT CARE FOR INTRACEREBRAL HEMORRHAGE
ADULT ECONOMIC STATUS AND OBESITY IN THE UNITED STATES
CLINICAL IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ≥65 YEARS WITH OVERACTIVE BLADDER
THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES
IMPACT OF PATIENT SELECTION CRITERIA AND MODEL SPECIFICATION ON COMPARISONS OF ALTERNATIVE THERAPIES
NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDERAND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003
USE PATTERNS AND OUTCOMES ASSOCIATED WITH TYPICAL DEPOT ANTIPSYCHOTIC AGENTS IN THE SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP)-AUSTRALIA
NICE'S COST-EFFECTIVENESS APPRAISAL OF CHOLINESTERASE INHIBITORS
MEDICAL COSTS AND HOSPTALIZATION OF ADULTS DIAGNOSED WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER WHO RECEIVED ALTERNATIVE THERAPIES
THE ECONOMIC IMPACT OF EPOETIN ALFA (EPO) THERAPY ON DELAYING TIME TO DIALYSIS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)
ECONOMIC BURDEN OF UNTREATED ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) PATIENTS
FACTORS ASSOCIATED WITH CARE SEEKING FOR OVERACTIVE BLADDER SYMPTOMS
THE COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES FORABNORMAL UTERINE BLEEDING
ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS
MAMMOGRAPHY SCREENING USE AMONG MEDICARE BENEFICIARIES AGE 65 OR OLDER
COLONOSCOPY PROCEDURE RATES AMONG PRIVATE-PAY PATIENTS INCREASED SUBSTANTIALLY BETWEEN 2000 AND 2004
COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING
INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION IN THE UNITED STATES
IMPACT OF VENTRICULAR ARRHYTHMIA ON MORTALITY, HEALTH CARE UTILIZATION AND COST IN HOSPITALIZED ACUTE MYOCARDIAL INFARCTION PATIENTS
SWITCHING, AUGMENTATION AND TITRATION OF LIPID LOWERING AGENTS OF MEDICARE/MEDICAID DUAL ELIGIBLE PATIENTS BY ETHNICITY
MANAGING CONGESTIVE HEART FAILURE
“GATEKEEPERS AND SENTINELS”
OUTCOMES ASSOCIATED WITH ANTIFUNGAL DRUG SWITCHING IN PATIENTS WITH SERIOUS CANDIDA INFECTIONS
TRENDS IN HIVTREATMENT EXPERIENCE AND OUTCOMES AS OBSERVED IN A SAMPLE OF PATIENTS FROM A US CLINICAL DATABASE
COMPLIANCE WITH ANTIBIOTIC TREATMENT GUIDELINES IN MEDICARE MANAGED CARE PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN AMBULATORY SETTINGS
THE INDIRECT COST BURDEN OF MIGRAINE AMONG SEVERAL LARGE U.S. EMPLOYERS
EVALUATIONS OF THE PRESCRIBED DAILY DOSES OF TRANSDERMAL FENTANYL AND TRANSDERMAL BUPRENORPHINE IN CANCERAND NON-CANCER PATIENTS IN GERMANY
A DESCRIPTION OF OFFICE VISIT RATES AND PRESCRIPTION USE FOR INSOMNIA AMONG RECIPIENTS OF A STATE MEDICAID PROGRAM
IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON WORKPLACE PRODUCTIVITY
PRESCRIPTION FOR LONGER LIFE
ACTIVE SAFETY SURVEILLANCE FORTU-HUO-CHI-SHENG-TANG
RETROSPECTIVE STUDY ON THE ADVERSE EVENTS OF ARTHRITIC PATIENTS TREATED WITH VIOXX AND OTHER ARTHRITIS PAINKILLERS
COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS IN THE UK
COST-EFFECTIVENESS OF RITUXIMAB AS A NEW TREATMENT MODALITY FOR RHEUMATOID ARTHRITIS IN GERMANY
MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
MODELLING OF THE COST-EFFECTIVENESS OF RITUXIMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY
USING MABTHERA IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN
A PHARMACOECONOMIC EVALUATION FORTHE TREATMENT OF ARTICULAR PAIN IN PATIENTS WITH OSTEOARTHRITIS IN MEXICO
COST-EFFECTIVENESS OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS
COST-EFFECTIVENESS ANALYSIS FOR TREATMENTS IN ANKYLOSING SPONDYLITIS
A COST-EFFICACY ANALYSIS MODEL FOR ANTI-TNF AGENTS IN PSORIATIC ARTHRITIS
A PROSPECTIVE STUDY COMPARING DRUG UTILIZATION PATTERNS AND COST OF TREATMENT OF PATIENTS FOR RHEUMATOID ARTHRITIS IN KERALA, INDIA
WITHDRAWAL OF COX-2 INHIBITOR ROFECOXIBAND VALDECOXIB
PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS
CAN OSTEOARTHRITIS PATIENTS EVALUATE TRADEOFFS BETWEEN NSAID RISKS AND BENEFITS?
A COMPARISON OF HEALTH RELATED QUALITY OF LIFE (HRQOL) OF PERSONS WITH AND WITHOUT ARTHRITIS OR CHRONIC JOINT SYMPTOMS (CJS)
HEALTH-RELATED QUALITY OF LIFE (HRQL) IN OSTEOARTHRITIS
WITHDRAWN
BENEFIT-RISK-COST TRADE-OFF ANALYSES USING PATIENT PREFERENCES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
RETROSPECTIVE STUDY OF INSULIN GLARGINE USE IN PREVIOUSLY INSULIN-NAIVE U.S. MANAGED CARE PATIENTS WITH TYPE 2 DIABETES
WITHDRAWN
EARLY HEALTH TECHNOLOGY ASSESSMENT
WITHDRAWN
NEGATIVE PRESSURE WOUND THERAPY ASSOCIATION WITH REDUCED OCCURRENCE OF DIABETIC FOOT ULCER AMPUTATIONS
FACTORS ASSOCIATED WITH DIABETES CONTROL IN A LATINO POPULATION USING A HEALTH BEHAVIOR MODEL APPROACH
COST IMPACT ASSOCIATED WITH INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS
ECONOMIC IMPACT OF AUGMENTATION THERAPY IN TYPE 2 DIABETES PATIENTS INITIATED ON SULFONYLUREAS
PHARMACOECONOMIC ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN TYPE II DIABETICS
MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES
LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE + METFORMIN VERSUS NATEGLINIDE + METFORMIN IN TYPE 2 DIABETES PATIENTS WITH INADEQUATE GLYCEMIC CONTROL ON MONOTHERAPY
A MARKOV MODEL TO ASSESS THE COST-EFFECTIVENESS OF A CONTINUOUS GLUCOSE MONITORING SYSTEM WITH TRENDING AND RATE INFORMATION WHEN USED TO PREDICT AND PREVENT HYPO-AND HYPERGLYCEMIA IN PATIENTS WITH TYPE 1 DIABETES
COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN ADDING FENOFIBRATE TO TREATMENT WITH A STATIN
MODELLING THE EFFECTIVENESS OF ORAL AGENTS IN ACHIEVING HBAIC AND LIPIDTARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
COST-UTILITY ANALYSIS OF ANALOG BASAL BOLUS THERAPY AMONG INSULIN-DEPENDENT DIABETES PATIENTS
BASAL BOLUS THERAPY AMONG TYPE I DIABETES PATIENTS
MODELING THE COST-UTILITY OF REDUCED HYPOGLYCEMIAANDWEIGHT GAIN AMONG TYPE 2 DIABETES PATIENTS NEWLY INITIATED ON BASAL INSULIN
ECONOMIC BURDEN OF DIABETES ATTRIBUTABLE TO OVERWEIGHT AND OBESITY AMONG U.S. ADULTS
IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS
BLOOD GLUCOSE MONITORING RECOMMENDATIONS AND PRACTICES IN PATIENTS WITH TYPE 2 DIABETES
ANTIDIABETIC MEDI CATION PRESCRIBING TRENDS IN FRANCE
RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDY WITH PROPENSITY SCORE METHODS
EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL EQUATIONS (UKPDS 68), ANDTHE UKPDS RISK ENGINE EQUATIONS (UKPDS 56 AND 60) IN FORECASTING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES
EFFECTS OF INDUCING CORRELATION AMONG CHOLESTEROL PARAMETERS ON OUTCOMES IN SIMULATION OF PHARMACEUTICAL EFFECTIVENESS
MARGINAL STRUCTURAL MODELS—AN EXPLANATION AND ILLUSTRATION
ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—A METHODOLOGICAL COMPARISON USING A CLAIMS DATABASE
ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—COMPARISON OF RESULTS WITH AND WITHOUT PROPENSITY SCORING
DEVELOPMENT OF NEW INDICES OF GLYCEMIC CONTROL IN PATIENTS WITH DIABETES USING DIGITAL SIGNAL PROCESSING
IMPACT OF TYPE OF PHARMACY (CHAIN VERSUS INDEPENDENT) ON MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES
COSTS AND ADHERENCE ASSOCIATED WITH LONG TERM USE OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS
ASSOCIATION BETWEEN RACE AND MEDICATION ADHERENCE IN TYPE 2 DIABETES MEDICAID ENROLLEES
A SYSTEMATIC REVIEW OF ADHERENCE WITH DIABETES TREATMENT AND THE IMPACT OF NON-ADHERENCE ON HEALTH CARE COSTS
THE RELATIONSHIP BETWEEN HEALTH RELATED QUALITY OF LIFE (HRQOL)AND PAIN RESPONSE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS—TYPE 1 AND TYPE 2
TOPIRAMATE TREATMENT IMPROVES QUALITY OF LIFE (QOL)AND NERVE FUNCTION IN PATIENTS WITH DIABETIC NEUROPATHY (DN)
EQ-5D IN TYPE 2 DIABETES
PATIENT-REPORTED UTILITIES/DISUTILITIES ASSOCIATED WITH TREATMENTS FOR TYPE 2 DIABETES
A LITERATURE REVIEW OF TREATMENT SATISFACTION, ADHERENCE AND QOL INSTRUMENTS USED IN TYPE 1 AND 2 DIABETES
DIABETIC PATIENTS' PREFERENCE FOR INHALED INSULIN
HEPATITIS B IMMUNISATION FOR NEWBORNS OF HEPATITIS B SURFACE ANTIGEN-POSITIVE MOTHERS
DOSE-RESPONSE RELATION OF INTERFERON-ALPHA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B
MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN
COMPARATIVE EFFICACY OF LAMIVUDINE WITH ADEFOVIR IN PATIENTS WITH HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B
COMPARING THE COST-EFFECTIVENESS OF THE INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV)
COST-EFFECTIVENESS OF SCREENING PRISON POPULATION OF MARYLAND CORRECTIONAL FACILITIES FOR HEPATITIS C
COST-EFFECTIVENESS (C-E) OF TEGASEROD VS. PLACEBO FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
A COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR ESOPHAGEAL VARICES
COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH CHRONIC HEPATITIS C
COST OF ILLNESS IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE
ECONOMIC BURDEN OF ENDOSCOPY-RELATED INFECTIONS, PSEUDO-INFECTIONS AND TOXIC REACTIONS
COST-UTILITY ANALYSIS OF TEGASEROD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME
A COST UTILITY ANALYSIS OF PEGUINTERFERON ALFA 2B (12KD) (PEG2B)VERSUS PEGUINTERFERON ALFA 2A (40KD) (PEG2A) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN BRAZIL
COST-UTILITY OF A MODALITY OF “C” VIRUS HEPATITIS TREATMENT IN PATIENTS THAT DO NOT RESPOND TO INTERFERON PLUS RIBAVIRIN IN MEXICO
PRIOR AUTHORIZATION AND THE APPROPRIATE PRESCRIBING OF TEGASEROD
TRENDS OF GASTRIC ACID-SUPPRESSIVE DRUG USE IN THE GENERAL PRACTICE OF UK FROM 1995 TO 2005
TRENDS IN AMBULATORY CARE UTILIZATION FOR CONSTIPATION AND IRRITABLE BOWEL SYNDROME
A NEW APPROACH TO USING SELF-REPORTED UTILIZATION TO ESTIMATE COST ASSOCIATED WITH MILD, MODERATE, AND SEVERE GERD-RELATED SYMPTOMS
OBJECTIVE MEASUREMENT OF PRODUCTIVITY WHILE AT WORK IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE
SUBJECTIVE REASONS FOR NONCOMPLIANCE WITH MEDICATION REGIMEN IN INFLAMMATORY BOWEL DISEASE PATIENTS
ADHERENCE AND RIBAVIRIN DOSE AS CRITICAL SUCCESS FACTORS TO THE CHRONIC HEPATITIS C (CHC) TREATMENT
WEIGHING TREATMENT BENEFITS AGAINST TREATMENT RISKS
THE EXCESS PREVALENCE OF COMORBIDITIES ASSOCIATED WITH ERECTILE DYSFUNCTION IN A LARGE STATE MEDICAID PROGRAM
A COST EFFECTIVENESS STUDY OF CARBETOCINE COMPARED TO OXYTOCIN FOR THE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS
COST-EFFECTIVENESS ANALYSIS OF ORAL PHARMACOLOGICAL TREATMENTS OF ERECTILE DYSFUNCTION
ECONOMIC BURDEN OF ABNORMAL UTERINE BLEEDING
A SYSTEMATIC REVIEW OF ATROPHIC VAGINITIS TREATMENT, DURATION OF THERAPY, AND HEALTH CARE COSTS
MEDICAL RESOURCE UTILIZATION IN DIAGNOSED PREMATURE EJACULATION PATIENTS
APPROPRIATE MEDICATION PRESCRIBING FORTHE ELDERLY
TEXAS COMMUNITY PHARMACISTS'WILLINGNESS TO ACCEPT PHARMACIST INITIATED EMERGENCY CONTRACEPTION
THE TRANSLATION AND CULTURAL ADAPTATION OF AN ADOLESCENT SEXUAL BEHAVIOUR QUESTIONNAIRE
DEVELOPMENT AND VALIDATION OF THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY
SURVEY ASSESSMENT OF TREATMENT COMPLIANCE AND MEDICATION TAKING BEHAVIOR IN BENIGN PROSTATIC HYPERPLASIA
COMPLIANCE WITH PRESCRIBED ONCE A DAY PLACEBO IN ADOLESCENT HEALTHYVOLUNTEERS
RECALL PERIODS FOR SATISFACTION WITH SEXUAL INTERCOURSE
BARRIERS TO COMMUNICATION ABOUT ERECTILE DYSFUNCTION IN PATIENTS TAKING ANTIHYPERTENSIVE MEDICATIONS
WHAT EXPECTATIONS DO MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH) HAVE FOR TREATMENT?
DEVELOPMENT OF A PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE FOR BENIGN PROSTATIC HYPERPLASIA (BPH-PSTQ)
EXPLORATORY FACTOR ANALYSIS OF A 13 ITEM BPH PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE (BPH-PSTQ)
TRANSFERABILITY OF ECONOMIC EVALUATIONS
HEALTH CONDITIONS IN POSTMENOPAUSAL WOMEN AND IMPLICATIONS FOR THE DESIGN OF CLINICAL TRIALS OF AROMATASE INHIBITORS
HOW MUCH DOES A DAY IN THE HOSPITAL COST?
THE LEVEL OF AWARENESS OFTMC PHYSICIANS ON THE PRICES OF COMMONLY PRESCRIBED MEDICATIONS AND DIAGNOSTIC PROCEDURES AND ITS EFFECT ON THEIR PRESCRIBING PREFERENCES
ARE NON-INFERIORITYTRIALS SUITABLE FOR ECONOMIC EVALUATION? ESTIMATION IS STILL MORE IMPORTANT THAN HYPOTHESIS TESTING
A STANDARDIZED METHODOLOGYTO MEASURE MEDICINE PRICES, AVAILABILITY, AFFORDABILITY AND PRICE COMPONENTS IN DEVELOPING AND TRANSITIONAL COUNTRIES
AN INTERACTIVE ECONOMIC MODEL FOR VACUUM ASSISTED CLOSURE THERAPY
THE USE OF QUINTILE ANALYSIS ASA MEASURE OF DISEASE SEVERITY
THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY
DEVELOPMENT OF A GLOBAL HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER
THE COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY
PREVAILING JUDGMENTS ABOUT SOCIETY'S WILLINGNESS TO PAY FORA QALY
INTERNET-BASED UTILITY ELICITATION OF A GENERIC HEALTH STATE
GENERAL HEALTH STATUS AND PATIENT SATISFACTION
MULTI-METHOD QUALITATIVE APPROACH TO DEVELOP COMPREHENSIVE PATIENT-REPORTED OUTCOME MEASURES
THE PROLABELS DATABASE
EVALUATING THE STRENGTH OF EVIDENCE OF CHANGE
A BAYESIAN APPROACH TO PREDICT EFFECTIVENESS OF NEWLY INTRODUCED DRUGS IN DAILY PRACTICE BASED ON THE RELATION BETWEEN EFFICACY AND EFFECTIVENESS OF COMPETING INTERVENTIONS
DEVELOPMENT AND VALIDATION OF A SCALE TO MEASURE PATIENTS'TRUST IN PHARMACISTS IN SINGAPORE
ALLOCATION OF PRESCRIPTION DATA BY INDICATION
NOT ALL PATIENTS ARE AVERAGE
BAYESIAN ESTIMATION OF COST-EFFECTIVENESS ADJUSTED FOR REAL WORLD CONSIDERING STATISTICAL ERRORS IN CLINICAL TRIALS
MEASURING SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES
CONVERTING SF-36 INTO EQ-5D
CRITERIA FOR IDENTIFYING PATIENTS WITH DEMENTIA AND PREVALENCE ESTIMATES OF DEMENTIA AMONG INDIANA MEDICAID RECIPIENTS
META-ANALYSIS OF ANTIDEPRESSANTTREATMENT EFFECTS IN PATIENTS AFTER STROKE
AUSTRALIAN SCHIZOPHRENIC PATIENTS TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)
META-ANALYSIS OF SNRIS, SSRIS, AND TCAS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER USING REMISSION AS THE CLINICAL OUTCOME
INCIDENT DIABETES ASSOCIATED WITH USE OF SECOND-GENERATION ANTIPSYCHOTIC (SGA) THERAPY
NEW-ONSET DIABETES MELLITUS ASSOCIATED WITH USE OF ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIC PATIENTS IN TAIWAN
ANNUAL COSTS ASSOCIATED WITH PATTERNS OF ANTIDEPRESSANT TREATMENT RESPONSE AMONG EMPLOYEES
COST-EFFECTIVENESS OF VENLAFAXINE
COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF ACUTE MANIA
COST AND EFFECTIVENESS OF SWITCHING FROM RISPERIDONE TO OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA
A COST-EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CHRONIC SCHIZOPHRENIA IN MEXICO
AN ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTIC FOR BIPOLAR DISORDER IN THE NC MEDICAID PROGRAM
AN ECONOMIC COST ANALYSIS OF ATYPICAL ANTIPSYCHOTIC SINGLE TREATMENT FOR BIPOLAR DISORDER IN A MEDICAID PROGRAM
BURDEN OF ILLNESS OF ALZHEIMER'S PATIENTS IN COMMERCIAL MANAGED CARE
BURDEN OF ILLNESS AMONG PATIENTS WITH ALZHEIMER'S DISEASE IN A COMMERCIALLY-INSURED POPULATION
HEALTH CARE COSTS AND UTILIZATION PATTERNS OF INDIVIDUALS WITH GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED STATES
RESOURCE-USE AND COSTS ASSOCIATED WITH PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE
ANALYZING PATTERNS OF ANTIDEPRESSANT USE AND THE COST CONSEQUENCES OF PRODUCT SWITCHING
ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-TERM INPATIENT TREATMENT FOR SCHIZOPHRENIA
COST OF TREATMENT OF HYPERKINETIC DISORDER IN GERMANY
HEALTH CARE RESOURCE UTILIZATION AND COST OF BIPOLAR I DISORDER WITH AND WITHOUT PSYCHOTIC SYMPTOMS
ANTIPSYCHOTIC POLYPHARMACY COSTS
HEALTH CARE RESOURCE UTILIZATION PRE/POST RISPERIDONE LONG-ACTING INJECTABLE TREATMENT INITIATION IN A MANAGED CARE POPULATION
INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS
LEARNING FROM NICE TECHNOLOGY ASSESSMENTS
REVIEW ON HEALTH OUTCOMES ASSOCIATED WITH DEPOT ANTIPSYCHOTIC AGENTS AND LONG-ACTING RISPERIDONE INJECTABLE (LARI) FOR TREATMENT OF SCHIZOPHRENIA
THE IMPACT OF PRESCRIBING OFF-LABEL MOOD STABILIZERS FOR PATIENTS WITH SCHIZOPHRENIA
SELECTION OF ATYPICAL ANTIPSYCHOTIC MONO-THERAPY FOR PATIENTS WITH BIPOLAR DISORDER
ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATION CLINICAL PRIOR AUTHORIZATION PROGRAM'S IMPACT ON PRESCRIPTION DRUG UTILIZATION AND COSTS
EVALUATION OF SELECTIVE SEROTONIN REPUTAKE INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION
LIKELIHOOD OF EMPLOYMENT TERMINATION FOR EMPLOYEES WITH BIPOLAR DISORDER TREATED WITH DIFFERENT PSYCHOTROPIC MEDICATIONS
ANTIPSYCHOTIC THERAPY IN PATIENTS WITH BIPOLAR DISORDER
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS PRESCRIBED ANTIPSYCHOTIC (AP) MONOTHERAPY IN TEXAS MEDICAID
DETERMINANTS IN ANTIDEPRESSANT TREATMENT SELECTION FOLLOWING THE INTRODUCTION OF DULOXETINE
THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
VARIATIONS IN THE OPERATIONAL DEFINITION OF MOOD DISORDERS IN RETROSPECTIVE CLAIMS DATABASE STUDIES
COMPARING ADHERENCE AND PERSISTENCE WITH ANTIPSYCHOTIC THERAPY AMONG PATIENTS WITH BIPOLAR DISORDER
ADHERENCE LEVELS AND DIFFERENTIAL USE OF MENTAL HEALTH SERVICES IN THE TREATMENT OF SCHIZOPHRENIA
COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS
ATYPICAL ANTIPSYCHOTIC COMPLIANCE AND PERSISTENCE AND ASSOCIATED HEALTH CARE UTILIZATION IN THE TREATMENT OF SCHIZOPHRENIA
PREDICTORS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
COMPLIANCE AND PERSISTENCE
RAMIFICATIONS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
ECONOMIC CONSEQUENCES OF PATIENTS NOT ADHERING TO MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA
DURATION OF ANTIPSYCHOTIC SWITCHING PROCESS IN THE NATURALISTIC TREATMENT OF SCHIZOPHRENIA
HEALTH-RELATED QUALITY-OF-LIFE MEASURED BY EQ-5D IN PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE
THE MISSION IS REMISSION–HEALTH ECONOMIC CONSEQUENCES OF ACHIEVING REMISSION WITH ANTIDEPRESSANT TREATMENT FOR DEPRESSION
MEASUREMENT OF UTILITY LOSSES IN DEPRESSION
CLINICAL EFFECTIVENESS AND HEALTH OUTCOMES OF DISEASE MODIFYING TREATMENT (DMT) THAT DELAYS DISABILITY PROGRESSION IN RELAPSING/REMITTING-ONSET MULTIPLE SCLEROSIS
RESTLESS LEGS SYNDROME
HOSPITAL LENGTH OF STAY ASSOCIATED WITH ANTICONVULSANT UTILIZATION BY PATIENTS WITH SEIZURE DISORDERS IN THE U.S.
COMPARING THE RELATIVE COST-EFFECTIVENESS OF ORAL PROPHYLACTIC MEDICATION VS. BOTULINUM TOXIN TYPE A (BOTOX®) IN THE MANAGEMENT OF MIGRAINE HEADACHE
ASSESSING ABSOLUTE REDUCTIONS IN CLINICAL EFFECT
EXAMINATION OF THE COST-EFFECTIVENESS OF DOPAMINE AGONISTS FOR THE TREATMENT OF RESTLESS LEGS SYNDROME
COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES
ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORY THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA
COST-EFFECTIVENESS OF TOPIRAMATE FOR MIGRAINE PREVENTION
COST-EFFECTIVENESS OF MS DISEASE MODIFYING AGENTS
COMPARING APPLES WITH WHAT
COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN
WINNERS AND LOSERS
COST-EFFECTIVENESS OF PREGABALIN AS ADJUNCT TO STANDARD THERAPY IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY
COST-OF-ILLNESS FOR ADULTS WITH PARTIAL EPILEPSY IN SWEDEN
ECONOMIC BURDEN OF PAIN DUE TO MULTIPLE SCLEROSIS IN CANADA
ECONOMIC COSTS OF CHRONIC PRIMARY INSOMNIA IN THE UNITED STATES
DIRECT COST BURDEN OF MIGRAINE AMONG MEMBERS OF US EMPLOYER GROUPS
ECONOMIC BURDEN OF RESTLESS LEGS SYNDROME IN A PRIVATELY-INSURED POPULATION
HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE SCLEROSIS IN A COMMERCIAL MANAGED CARE ENVIRONMENT
PATTERNS OF TOPIRAMATE UTILIZATION AMONG MEDICAID PATIENTS
ESTIMATING THE COST OF NURSING HOME CARE FOR PATIENTS WITH PARKINSON'S DISEASE USING RETROSPECTIVE DATABASE ANALYSIS
CONTROLLING SELECTION BIAS ON CONTINUOUS VARIABLES
THE ESTIMATION POWER OF ALTERNATIVE COMORBIDITY INDEXES
FAILURE OF REGRESSION ADJUSTMENT AGAINST PROPENSITY SCORE MATCHING
EXTENDING MATCHING ESTIMATORS OF CAUSAL EFFECTS TO CONSIDER UNOBSERVED VARIABLE BIAS
THE EFFECT OF ADHERENCE TO ALZHEIMER'S DISEASE TREATMENT ON HEALTH CARE COSTS IN MANAGED CARE
STUDYING DISCONTINUATION, SWITCHING, AND AUGMENTATION USING COMPETING RISK METHODS
A REVIEW OF THE VALIDITY AND RELIABILITY OF THE PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-39)
COMPARISON OF HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN MULTIPLE SCLEROSIS
HEALTHCARE UTILIZATION AND PATIENT SATISFACTION WITH TRIPTAN TREATMENT IN MIGRAINEURS
EVALUATION OF THE IMPACT OF AN EMPLOYEE WORKSITE DISEASE MANAGEMENT PROGRAM FOR MIGRAINEURS ON WORK PRODUCTIVITY
ASSOCIATION BETWEEN BMI AND HEALTH CARE EXPENDITURES USING THE 2002 MEDICAL EXPENDITURE PANEL SURVEY
COSTS OF PREMATURE DEATH ATTRIBUTED TO OBESITY IN SPAIN
COST-UTILITY ANALYSIS OF RIMONABANT IN THE TREATMENT OF OBESITY
USE OF GROWTH CURVE ANALYSES FOR DISCRETE EVENT SIMULATION
THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED QUALITY OF LIFE AMONG US ADULTS
SELF-IMAGE SCALE
OBESITY AND QUALITY OF LIFE IN THE UNITED STATES
IMPACT OF ABDOMINAL OBESITY ON QUALITY OF LIFE
EFFECT OF RIMONABANT ON QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS
SURVIVAL AMONG COPD PATIENTS USING FLUTICASONE/SALMETEROL IN COMBINATION VERSUS OTHER INHALED STEROIDS AND BRONCHDIALATORS ALONE
EVALUATION OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG COPD PATIENTS USING INHALED CORTICOSTEROIDS ORANTICHOLINERGIC AGENTS IN A MANAGED CARE POPULATION
COMBINATION THERAPY [LONG ACTING BETA AGONISTS (LABA) PLUS INHALED CORTICOSTEROIDS] VERSUS LABA ALONE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LIFETIME COSTS AND IMPACT ON LIFE EXPECTANCY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE U.S.
RESOURCE USE AND COST OF HEALTHCARE SERVICES AMONG PATIENTS NEWLY DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS
TOBACCO SMOKING AND DIRECT COSTS OF TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS
TREATING DOCTOR AND DIRECT COSTS OF HOSPITALIZATION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS
THE COST-EFFECTIVENESS OF PALIVIZUMAB IN AUSTRIA
EVALUATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS INITIATING AN INHALED CORTICOSTEROID OR AN ANTICHOLINERGIC IN A MANAGED CARE POPULATION
PREVALENCE OF NEUROGENIC BLADDER IN PATIENTS WITH VARIOUS NEUROLOGIC DISORDERS IN THE UNITED STATES
ASSOCIATION BETWEEN IN-HOSPITAL FALLS, COMORBIDITIES, AND DRUG USE IN ADULT CHRONIC KIDNEY DISEASE PATIENTS
ECONOMIC IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY-INSURED PERSONS ≥65 YEARS OF AGE WITH OVERACTIVE BLADDER
ELEVATED INTACT PARATHYROID HORMONE LEVELS AND HEALTH CARE COSTS AND UTILIZATION
EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS IN ANEMIC PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
EVALUATING THE OUTCOME AND COST ASSOCIATED WITH ATAMSULOSIN REAUTHORIZATION PROGRAM
FACTORS INFLUENCING EARLY NEPHROLOGY CARE PRIOR TO HEMODIALYSIS INITIATION AMONG ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE
ONE SOLUTION TO THREE PROBLEMS
ESTIMATING A PREFERENCE-BASED INDEX FROM A CONDITION SPECIFIC MEASURE-THE KING'S HEALTH QUESTIONNAIRE
PSYCHOMETRIC PROPERTIES OF THE KING'S HEALTH QUESTIONNAIRE
ESTIMATING A PREFERENCE-BASED SINGLE INDEX FROM THE OVERACTIVE BLADDER QUESTIONNAIRE
QUALITY OF LIFE IN YOUNG MEN AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER
GENERIC VS. DISEASE-SPECIFIC SATISFACTION MEASURES
WORK PRODUCTIVITY IN PATIENTS WITH OVERACTIVE BLADDER
DIAGNOSTIC TESTING FOR ALLERGIC RHINITIS
LEAVING AGAINST MEDICAL ADVICE (LAMA) IN ASTHMA EXACERBATION
DRUG ADVERSE EVENTS MODIFYTHE TREATMENT AND COMPLIANCE OF ASTHMA PATIENTS
ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA
ECONOMETRIC MODELING IN CHRONIC ASTHMA ALLOWS COMPARISONS BETWEEN DIFFERENT THERAPY GROUPS
RELATIONSHIP OF PATIENT CHARACTERISTICS AND RESOURCE USE IN SEVERE ASTHMA
WITHDRAWN
COMPUTERIZED DECISION SUPPORT FOR ASTHMA MANAGEMENT
IMPROVING ASTHMA SELF-MANAGEMENT AND PATIENT OUTCOMES USING AN AUTOMATED PROGRAM
THE PERFORMANCE OF BOOTSTRAPPING IN DISCRETE CHOICE MODELS
A SYSTEMATIC OVERVIEW OF THE MEASUREMENT PROPERTIES OF THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN ASTHMA
PROPENSITY SCORE MATCHING WITH MORE THAN TWO CATEGORIES
TREATMENT PERSISTENCE AND COMPLIANCE WITH MEDICATIONS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
ASSOCIATION OF MEDICATION ADHERENCE WITH WORKPLACE PRODUCTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ASTHMA
ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG CANCER ADJUVANT TREATMENTS IN PRACTICE USING INSTRUMENTAL VARIABLE METHODS
EFFECTIVENESS OF A COMMUNITY–BASED PROSTATE CANCER EDUCATION KIOSK FOR AFRICAN AMERICAN MEN
AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR DELAYED NAUSEA AND VOMITING USING ELECTRONIC MEDICAL RECORDS
RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF ENDOMETRIAL CANCER
QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH BREAST CANCERAND ITS ECONOMIC CONSEQUENCES IN MEXICO
HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH CANCERAND PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD)
WITHDRAWN
COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN
ECONOMIC EVALUATION OFANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
COST-EFFECTIVENESS OF GEMCITABINE-PACLITAXEL COMBINATION IN THE TREATMENT OF ADVANCED BREAST CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY
COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER
COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL) RECEIVING CHOP
COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY
COST-EFFECTIVENESS OFTAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER
THE ANNUAL HEALTH INSURANCE COST OF COLORECTAL CANCER TREATMENT IN HUNGARY
ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS
EVALUATING THE COST OF CARE FOR EARLY AND LATE STAGE OROPHARYNGEAL CANCER IN THE CALIFORNIA MEDICAID POPULATION
CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY
COLONOSCOPYAND FLEXIBLE SIGMOIDOSCOPY
COSTS OF THE DIFFERENT TREATMENTS FOR PATIENTS WITH BREAST CANCER IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
4D LOCALIZATION SYSTEM WITH TRANSPONDERS FOR CONTINUOUS TARGET LOCALIZATION FOR SET-UP AND TRACKING DURING RADIATION THERAPY
THE EFFECT OF EFFICIENCY OF ACCESS TO CARE
THE EFFECT OF ORGANIZED MAMMOGRAPHY SCREENING ON THE NUMBER OF BREAST SURGERIES
DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT–AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL
REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A NATIONWIDE SAMPLE OF PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY
INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS
REVIEW OF ECONOMIC APPRAISALS OF CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER
GAPS IN THE ECONOMIC EVALUATION OF PROSTATE CANCER
WITHDRAWN
A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES
MODELING AND ESTIMATING PREFERENCES OVER TREATMENTS FOR BREAST CANCER
MAPPING FACT-P AND EORTC QLQ-C30TOTHE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS
VALIDATION OF AN INTERNET-BASED PATIENT HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE
DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC, NEUROENDOCRINETUMOR QUESTIONNAIRE (QOL-NET), TO MEASURE PATIENTS' PERCEPTION OF THE EFFECTS OF DISEASE ON THEIR QUALITY OF LIFE (QOL)
DEVELOPING HEALTH STATE DESCRIPTIONS FOR METASTATIC COLORECTAL CANCER
ESTIMATION OF A SET OF PATIENT-BASED UTILITY WEIGHTS FOR THE FACT-G
PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP
A SYSTEMATIC REVIEW OF THE UCLA PROSTATE CANCER INDEX'S MEASUREMENT PROPERTIES
THE IMPACT OF HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER ON HEALTH-RELATED QUALITY OF LIFE
EQ-5D IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS
A SYSTEMATIC REVIEW OF THE EORTC QLQ-BR23
IMPROVEMENT IN SENSORY PAIN RATING AFTER PALLIATIVE RADIONUCLIDE THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER
EFFECT OF AGE ON PREFERENCES FOR HEALTH OUTCOMES IN PROSTATE CANCER
ONLINE REPORTING OFTOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY
USING ANTI-COAGULANTS AS PROPHYLAXIS FOR DVT/PE
RETROSPECTIVE STUDY OF PATIENTS WITH CABG REOPERATION AND OUTCOMES
THE IMPACT OF MYOCARDIAL PERFUSION IMAGING FOR DETECTION OF CORONARY ARTERY DISEASE ON THE HEALTH OUTCOMES OF ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES
A NATIONAL STUDY PREDICTING THE INFLUENCE OF PAYMENT SOURCES ON THE THIAZIDE DIURETICS UTILIZATION FOR HYPERTENSION
PATIENT RISK ASSESSMENT AND ENGAGEMENT IN PRIMARY CARE MANAGEMENT OF CARDIOVASCULAR RISK
MODELED ACHIEVEMENT OF OPTIMAL LIPID VALUES WITH EXTENDED-RELEASE NIACIN/LOVASTATIN VERSUS SIMVASTATIN/EZETIMIBE COMBINATION THERAPY IN AT-RISK PATIENTS
A PROSPECTIVE STUDY EVALUATING STREPTOKINASE THERAPY ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH MYOCARDIAL INFARCTION AT A TERTIARY CARE REFERRAL HOSPITAL IN KERALA, INDIA
OUTCOMES OF CONGESTIVE HEART FAILURE INPATIENTS TREATED WITH NESIRITIDE
CARDIOVASCULAR RISK PREDICTED BY ADHERENCE TO STATINS IN A MEDICAID POPULATION
LOSS OF COMBINED OPTIMAL LIPID VALUE ACHIEVEMENT AND THE RISK OF CARDIOVASCULAR EVENTS
EVALUATION OF A MAIL-BASED WARFARIN (COUMADIN®) PATIENT EDUCATION INITIATIVE IN A MANAGED CARE SETTING
ASSESSMENT OF THE EFFECTS OF ROFECOXIB, CELECOXIB AND NAPROXEN ON BLOOD PRESSURE AND CARDIOVASCULAR RISK
CLOPIDOGREL THERAPY AND HEALTH CARE COSTS FOLLOWING AN ACUTE CORONARY SYNDROME EVENT
WITHDRAWN
ATRIAL VERSUS DUAL CHAMBER PACING IN SINUS NODE DISEASE
ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
DECISION ANALYSIS TO COMPARE THE COST-EFFECTIVENESS OF THE STATINS AVAILABLE BY PRESCRIPTION VERSUS OVER THE COUNTER BASED FROM A SOCIETAL PERSPECTIVE
ECONOMIC EVALUATION OF ORAL THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION
ONE-YEAR COSTS FORACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT REVASCULARIZATION DURING THE INITIAL HOSPITALIZATION
MARKOV-BASED ECONOMIC ANALYSIS OF NESIRITIDE IN ACUTE DECOMPENSATED HEART FAILURE
COSTS OF DIAGNOSTIC PROCEDURES OF INTERVENTIONIST CARDIOLOGY IN THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
INPATIENT MANAGEMENT OF TRANSMURAL AND SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION (AMI)
AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT) IN BRAZIL
AFRICAN AMERICANS' RESPONSES TO DIRECT-TO-CONSUMER ADVERTISING (DTCA) OF LIPITOR®
USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY HYPERTENSIVE PATIENTS IN THE UNITED STATES
PRESCRIBING PATTERNS FOR ANTIHYPERTENSIVE DRUGS AFTERTHE PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) IN REGION EMILIA ROMAGNA (RER), ITALY
THE IMPACT OF DOSE INCREASE ON THE COST-EFFECTIVENESS OF STATINS
ECONOMIC EVALUATION OF AN INTERDISCIPLINARY APPROACH TO HEART FAILURE MANAGEMENT
ANALYSES FOR PRICE AND UTILIZATION OF CALCIUM CHANNEL BLOCKERS IN US MEDICAID PROGRAMS
TREND ANALYSIS OF PRICE AND UTILIZATION OF STATIN DRUGS IN U.S. MEDICAID PROGRAMS
DRUG PRICE AND UTILIZATION OF BETA BLOCKERS IN US MEDICAID PROGRAMS
DRUG PRICE AND UTILIZATION OF ACE INHIBITORS IN US MEDICAID POPULATION
PRESCRIPTION DRUG INSURANCE STATUS AND UTILIZATION OF ANTI-HYPERLIPIDEMICS
DEVELOPING HOSPICE DRUG FORMULARY USING MULTI-ATTRIBUTE UTILITYTHEORY (MAUT) METHODOLOGY
SINGLE SOURCE COST ESTIMATES FOR EVENTS ACROSS VARIOUS CONDITIONS REQUIRING THROMBOEMBOLIC PROPHYLAXIS AND TREATMENT
RATE OF LOW-DENSITY LIPOPROTEIN (LDL) GOAL ATTAINMENT WITH LIPID LOWERING THERAPIES AT A LI PI D CLINIC IN A PUBLIC HOSPITAL OF HONG KONG–POSSIBLE ROLE OF A CLINICAL PHARMACY SERVICE
SURVEY OF PHYSICIAN ATTITUDES AND PRACTICES IN LIPID LOWERING MANAGEMENT
INITIAL PHARMACEUTICAL TREATMENT OF SIMPLE HYPERTENSION
PREDICTING ANTIHYPERTENSIVE DRUG UTILIZATION
VARIATION OF COST-TO-CHARGE RATIO FOR CABG PATIENT BY HOSPITAL TYPE OVERTIME
PROVISION OF DIET/NUTRITION AND EXERCISE COUNSELING FOR PATIENTS WITH DYSLIPIDEMIA BY AMBULATORY CARE PHYSICIANS IN THE UNITED STATES
PREDICTING HIGH COSTS IN CALIFORNIA MEDICAID PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)
AN EMPIRICAL EVALUATION OF THE EXPECTED VALUE OF PERFECT INFORMATION
THE CASE OF LI PI D-LOWERING THERAPY
RELIABILITY AND VALIDITY OF TAIWAN VERSION OF TREATMENT-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR PATIENTS RECEIVING ORAL ANTICOAGULATION
THE ALABAMA COLLABORATION FOR CARDIOVASCULAR EQUALITY PROJECT
AN APPROACH TO GENERALIZE CLINICAL TRIAL RESULTS TO NON-STUDY POPULATIONS FOR COST-EFFECTIVENESS EVALUATIONS—THE CASE OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS)
WITHDRAWN
PATIENT ADHERENCE TO AHA GUIDELINES PRE-AND POST AMI
STATIN THERAPY PERSISTENCE IN A MANAGED CARE POPULATION
OUTPATIENT DISCONTINUATION AND RESTARTING OF POST-MYOCARDIAL INFARCTION BETA-BLOCKER THERAPY
MEDICATION ADHERENCE
STATIN NONCOMPLIANCE AFTER CHD HOSPITALIZATION AND SUBSEQUENT HOSPITALIZATION AMONG NEW STATIN USERS
DETERMINANTS OF TREATMENT PERSISTENCE IN A GERMAN HYPERTENSIVE POPULATION
ADHERENCE MERASURES
PERSISTENCE WITH NEWLY-INITIATED EXTENDED-RELEASE NIACIN VERSUS OTHER LIPID MODIFYING DRUG CLASSES IN CLINICAL PRACTICE
DOES 90-DAY PRESCRIPTION SUPPLY AT RETAIL IMPROVE COMPLIANCE IN A MANAGED CARE SETTING?
ADHERENCE TO EVIDENCE-BASED STATIN GUIDELINES REDUCES RISK FORACUTE MYOCARDIAL INFARCTION WITH AT LEAST 50%.
LONG-TERM CARDIOVASCULAR OUTCOMES OF COMPLIANCE AND PERSISTENCE WITH HYPERTENSION THERAPY
IMPACT OF ADHERENCE TO ANTIHYPERLIPIDEMIC DRUGS ON TOTAL PHARMACY AND MEDICAL COSTS
DETERMINANTS OF ADHERENCE TO STATINS IN A MEDICAID MANAGED CARE POPULATION
UNDERSTANDING PATIENT BELIEFS TO DESIGN MEDICATION ADHERENCE MESSAGING
ASSOCIATION OFANTIHYPERTENSIVE MEDICATION CLASS WITH BLOOD PRESSURE CONTROL AND PERSISTENCE ON MONOTHERAPY
THE LEVEL AND LONG-TERM DYNAMICS OF THE QUALITY OF LIFE AS PREDICTORS OF ADHERENCE TO ROUTINE HYPERTENSION MANAGEMENT
PATIENT ADHERENCE WITH ANTIDIABETIC, ANTIHYPERTENSIVE, AND LIPID-LOWERING MEDICATIONS
A SYSTEMATIC REVIEW OF THE DISEASE-SPECIFIC AND THE GENERIC QUALITY-OF-LIFE INSTRUMENTS IN CONGESTIVE HEART FAILURE
PREDICTORS OF HIGH BLOOD PRESSURE KNOWLEDGE IN HYPERTENSIVE PATIENTS
BENEFICIAL IMPACT ON BLOOD PRESSURE CONTROL AMONG MEN PRESCRIBED SILDENAFIL CITRATE
ECONOMIC EVALUATION OF STRATEGIES FOR SCREENING NEWBORNS FOR BILATERAL HEARING IMPAIRMENT IN FRANCE
OUTCOMES ASSOCIATED WITH AN OTITIS PARENT QUESTIONNAIRE IN PEDIATRIC PATIENTS WITH ACUTE OTITIS MEDIA FOLLOWING ADMINISTRATION OF CEFDINIR ORAL SUSPENSION OR HIGH DOSE AMOXICILLIN/CLAVULANATE ORAL SUSPENSION
PREVALENCE OF INTRAOCULAR HYPERTENSION AND GLAUCOMA IN AN UNSELECTED FRENCH POPULATION
PREVALENCE AND DESCRIPTION OF TREATMENT WITH INTRAOCULAR PRESSURE LOWERING TOPICAL MEDICATIONS IN CONTINENTAL FRANCE
THE ECONOMIC IMPACT OF BLUE-LIGHT FILTERING INTRAOCULAR LENSES ON AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH CATARACT SURGERY
EVALUATION OF DIRECT MEDICAL COST OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN PATIENTS IN THE MEDICARE POPULATION
ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY (VISUDYNE®) COMPARED TO USUAL CARE IN THE TREATMENT OF AGE RELATED MACULAR DEGENERATION (ARMD) IN USA
REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0·05% WITHIN MANAGED CARE
VARIATIONS IN PHYSICIAN PRESCRIBING OF TOPICAL MEDICATIONS FOR GLAUCOMA IN US OUTPATIENT SETTINGS
ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA
COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS
ECONOMIC AND QUALITY OF LIFE BURDEN OF HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA
ECONOMIC ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE HOME TREATMENT OF MINOR-TO-MODERATE BLEEDS IN HEMOPHILIA PATIENTS WITH INHIBITORS
COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA
PILOT STUDY TO ESTABLISH PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES USED TO TREAT HAEMOPHILIC PATIENTS WITH INHIBITORS
A COMPARISORN OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION
MEMBERS INITIAL EXPERIENCE WITH A CONSUMER-DRIVEN PHARMACY BENEFIT PLAN DESIGN
IMPACT OF CONSUMER-DIRECTED HEALTH PLAN ON PHARMACY UTILIZATION
OUT-OF-POCKET PRICE OF OUTPATIENT MEDICATIONS IN THE UNITED STATES
WITHDRAWN
BENEFICIARIES' OUT-OF-POCKET COSTS UNDER THE MEDICARE PRESCRIPTION DRUG BENEFIT
THE DECISION TO CONDUCT A HEAD-TO-HEAD COMPARATIVE TRIAL
BRITISH COLUMBIAN PHYSICIANS' OPINIONS REGARDING REFERENCE DRUG AND GENERIC SUBSTITUTION PROGRAMS
SUMMARY OF THE FIRST YEAR OF A DISEASE MANAGEMENT PROGRAM IN PATIENTS WITH BLEEDING DISORDERS
CHARACTERISTICS OF SENIORS WITH HIGH ANNUAL PRESCRIPTION DRUG EXPENDITURES
PRESCRIPTION PATTERNS OF POTENTIALLY INAPPROPRIATE MEDICATIONS AMONG OLDER MEDICARE MANAGED CARE BENEFICIARIES
MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN RAJASTHAN, INDIA
ENHANCING THE SAFETY OF OTC MEDICATION USE FOR HISPANIC CONSUMERS WITH BILINGUAL LABELS
WITHDRAWN
THE CORRELATION OF SATISFACTION OF MEDICARE BENEFICIARIES WITH ACCESS AND QUALITY OF CARE
THE IMPACT OF THE PHARMACY AND THERAPEUTICS COMMITTEE ON THE PATIENTS'ACCESS TO PRESCRIPTION DRUGS IN THE SAUDI MINISTRY OF HEALTH
IMPACT OF CO-PAY DIFFERENTIAL ON GENERIC PRESCRIPTIONS FILLED THROUGH 90-DAY RETAIL CHANNEL
IMPACT OF STEPS (SAFE, THERAPEUTIC AND ECONOMIC PHARMACEUTICAL SELECTION) MODEL ON PRESCRIBING COSTS OF STATINS
COST SAVINGS ASSOCIATED WITH TABLET SPLITTING PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING
ISPOR CONTRIBUTED RESEARCH 1998–2005
CALCULATION OF LORENZ CONCENTRATION CURVES AND GINI COEFFICIENT OF HEALTH EXPENDITURES IN HUNGARY
PRESCRIPTION DRUG PRICE COMPARISONS BETWEEN CANADIAN AND US ON-LINE PHARMACIES OVER A SIX-MONTH PERIOD
EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS
ELECTRONIC INTERFACES FOR SHARING PATIENT DATA
HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PHARMACEUTICAL CARE
DEVELOPING A MEASURE OF PATIENT EMPOWERMENT TO BE APPLIED IN THE GENERAL COMMUNITY
CLUSTER ANALYSIS OF STATE MEDICAID PROGRAMS
THE EFFECT OF HIGH-RISK MEDICATIONS ON VISIT TIME WITH PHYSICIANS
WITHDRAWN
HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS INFECTION
COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS
THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C
ECONOMIC ANALYSIS OF LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING IN MILITARY RECRUITS
COST EFFECTIVENESS OF ADDING 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE TO A CHILDHOOD VACCINATION—IMPACT OF HERD IMMUNITY
COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS
WITHDRAWN
COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA IN ARGENTINA
ECONOMIC EVALUATION FORTHE ANTIMICROBIAL EMPIRIC TREATMENT OF HOSPITALIZED PATIENTS WITH VENTILATOR—ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS IN MEXICO
COST EFFECTIVENESS OF TIPRANAVIR IN TREATMENT-EXPERIENCED HIV PATIENTS IN THE USA
THE IMPACT OF MECHANICAL VENTILATION ON OUTCOMES AND COSTS IN NOSOCOMIAL PNEUMONIA
LIFETIME MEDICAL COST OF CHRONIC HEPATITIS B
COST OF THERAPY OF UPPER RESPIRATORY TRACT INFECTIONS IN A DEPRESSED ECONOMY
DIRECT MEDICAL COSTS OF PATIENTS WITH HIV/AIDS IN MEXICO
THE EXPECTED ECONOMIC BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI)
CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN ACUTE HOSPITALS
A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM
HOSPITAL LENGTH-OF-STAYAND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS
A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOMES IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL
COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE
USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION
USE OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING WITH MONTE CARLO SIMULATION TO REDUCE ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING PREDICTED EFFICACY
A REVIEW OF HERD EFFECTS IN THE ECONOMIC EVALUATION OF CHILDHOOD VACCINATIONS
HEALTH TECHNOLOGY ASSESSMENT
THE COST-EFFECTIVENESS OF EXTRACORPOREAL SHOCK WAVE THERAPY FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS
COMPARISON OF HOSPITAL COST WITH DRG REIMBURSEMENT RATE IN PATIENTS WITH PERITROCHANTERIC FRACTURE ACCORDING TO SURGICAL METHODS
ONE-AND TWO-YEAR PERSISTENT USE OF BISPHOSPHONATES REDUCES THE RISK OF OSTEOPOROTIC FRACTURES IN DAILY PRACTICE
THE EFFECT OF RISK FACTORS ON MORTALITY AFTER PRIMARY TREATMENT OF FEMORAL NECK FRACTURE AT DIFFERENT TIME PERIODS IN HUNGARY
BUDGET IMPACT ANALYSIS OF BISPHOSPHONATES FOR FRACTURES IN POSTMENOPAUSAL WOMEN
COMPARATIVE ANALYSIS OF HEALTH INSURANCE COST OF MEDIAL FEMORAL NECK FRACTURES WITH AND WITHOUT COMPLICATIONS ON A 2 YEARS FOLLOW UP
THE COST-EFFECTIVENESS OF IBANDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN THE US
COST OF FALLS IN LONG-TERM CARE FACILITIES (LTCFS)
CHANGES IN THE IMPAIRED ABILITY TO WORK IN PATIENTS UNDER 60 WITH MEDIAL FEMORAL NECK FRACTURE DURING 3 YEARS FOLLOW UP
PRICE AND UTILIZATION OF OSTEOPOROSIS MEDICATIONS IN U.S. MEDICAID PROGRAMS
TRENDS IN THE CLINICAL MANAGEMENT OF FRAGILE FRACTURE BEFORE AND AFTER THE NEW HED IS OSTEOPOROSIS MANAGEMENT MEASURE IN A MEDICARE POPULATION
TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PATIENTS WITH PAGET'S DISEASE TREATED WITH RISENDRONATE
THE USE OF INDIVIDUAL RISKS RATHER THAN POPULATION AVERAGES IN COST-EFFECTIVENESS MODELING
PATIENT ADHERENCE WITH BISPHOSPHONATES AT 6 MONTHS
COMPLIANCE, DISCONTINUATION, AND SWITCHING OF OSTEOPOROSIS TREATMENT IN LOUISIANA MEDICAID POST-MENOPAUSAL WOMEN
HOME AUTOMATED TELE MANAGEMENT IN POST-HIP FRACTURE REHABILITATION
INCIDENCE AND ECONOMIC IMPACT ANALYSIS OF HYPONATREMIA IN HOSPITALIZED PATIENTS
FATIGUE IN THE U.S. WORKFORCE
COST OF HOSPITALIZATIONS FOR ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS PRE-AND POST-REPEAL OF THE UNIVERSAL HELMET LAW IN FLORIDA
OPIOID ASSOCIATED ERECTILE DIS FUNCTION IN CHRONIC PAIN PATIENTS
IMPACT OF BACK PAIN ON ABSENTEEISM, PRODUCTIVITY LOSS, AND DIRECT HEALTH CARE COSTS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS
PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO PATIENT CONTROLLED ANALGESIA
ADVANCES IN PAIN MEASUREMENT
RESULTS OF ALTERNATIVE DEFINITIONS FOR STATIN REFILL COMPIANCE, PERSISTENCE AND GAPS IN A RETROSPECTIVE DATABASE ANALYSIS
SELF-REPORTED HEALTH STATUS PREDICTORS OF MEDICATION ADHERENCE IN OLDER ADULTS WITH CHRONIC DISEASES
EVALUATION OF A PROGRAM TO IMPROVE ADHERENCE WITH PEGYLATED INTERFERON THERAPY
PREVALENCE OF MEDICATION COMPLIANCE AND PERSISTENCY WITH SPECIALTY MEDICATIONS IN MANAGED CARE POPULATION
PHYSICIAN IMPRESSIONS AND USES OF PATIENT-REPORTED OUTCOMES DATA
PATTERNS FOR PHOTOTHERAPY USE IN TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
PHYSICIAN AND PATIENT RELATED DETERMINANTS OF PRESCRIBING TOPICAL CALCINEURIN INHIBITORS FOR PATIENTS WITH ATOPIC DERMATITIS
“HEALTH BENEFIT LIMITS” LIMIT TREATMENT OF PSORIASIS AND OTHER DERMATOLOGICAL CONDITIONS
MEDICATION-RELATED FACTORS AFFECTING HEALTH CARE OUTCOMES AND COSTS IN PATIENTS WITH PSORIASIS AND ACNE IN THE UNITED STATES
TREATMENT PATTERNS IN PATIENTS WITH SEVERE PSORIASIS
USING MEDIATION MODELS TO ASSESS THE INCREMENTAL VALUE OF QUALITY OF LIFE QUESTIONNAIRES
WITHDRAWN
POTENTIAL BENEFITS OF SMOKING CESSATION TREATMENT COVERAGE AT THE WORKPLACE
EFFECT OF SMOKING ON PERCEIVED HEALTH STATUS
COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA)
THE SHORT TERM COST-EFFECTIVENESS OF 45 SURGICAL INTERVENTIONS IN THE UK